AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12649866 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion titrated to a Bispectral Index near 60
Number of subjects: 8
Study 12649866 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical pulp stimulation (200 microamperes)
Number of subjects: 8
Study 12649866 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical pain stimulation on the right upper thigh (80 mA)
Number of subjects: 8
Study 10470750 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 64
Study 10470750 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 64
Study 7782484 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline, 100 mg
Number of subjects: 20
Study 7782484 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline, 200 mg
Number of subjects: 20
Study 7782484 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam, 1 mg
Number of subjects: 20
Study 7782484 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine, 10 mg
Number of subjects: 20
Study 7782484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2090472 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticarcillin (3,080 mosmol.kg-1)
Number of subjects: 12
Study 2090472 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (272 mosmol.kg-1)
Number of subjects: 12
Study 2090472 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin (248 mosmol.kg-1)
Number of subjects: 12
Study 660035 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypoxia (13.9% oxygen)
Number of subjects: 8
Study 660035 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe hypoxia (11.1% oxygen)
Number of subjects: 8
Study 660035 — intervention group
Group type: COMPARATOR
Intervention: Normal oxygen (20.9% oxygen)
Number of subjects: 8
Study 31996244 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical care based on the KTA framework
Number of subjects: 160
Study 31996244 — intervention group
Group type: COMPARATOR
Intervention: Routine medical care
Number of subjects: 160
Study 31465115 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture-method catheter
Number of subjects: 153
Study 31465115 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard perineural catheter
Number of subjects: 153
Study 31465115 — intervention group
Group type: COMPARATOR
Intervention: Single-injection
Number of subjects: 153
Study 28849797 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond Universal (self-etch)
Number of subjects: 48
Study 28849797 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond Universal (etch-and-rinse)
Number of subjects: 48
Study 28849797 — intervention group
Group type: COMPARATOR
Intervention: Adper Single Bond 2 (control)
Number of subjects: 48
Study 28849797 — intervention group
Group type: COMPARATOR
Intervention: Clearfil SE Bond (control)
Number of subjects: 48
Study 27324967 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch
Number of subjects: 3450
Study 27324967 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride (saline)
Number of subjects: 3450
Study 25099306 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication skills training program (TG)
Number of subjects: 115
Study 25099306 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 115
Study 22537421 — intervention group
Group type: EXPERIMENTAL
Intervention: Target hemoglobin level of 13.5 g/dL
Number of subjects: 1432
Study 22537421 — intervention group
Group type: COMPARATOR
Intervention: Target hemoglobin level of 11.3 g/dL
Number of subjects: 1432
Study 22537421 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher hemoglobin target with current smoking
Number of subjects: 1432
Study 22537421 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher hemoglobin target without current smoking
Number of subjects: 1432
Study 19666395 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose N-acetylcysteine (2800 mg/daily)
Number of subjects: 21
Study 19666395 — intervention group
Group type: COMPARATOR
Intervention: Low-dose N-acetylcysteine (700 mg/daily)
Number of subjects: 21
Study 17490437 — intervention group
Group type: EXPERIMENTAL
Intervention: Open irrigation tip (OIT) technology; temperature and power set at 50 degrees and 50 W, saline pump flow rate of 30 mL/min
Number of subjects: 53
Study 17490437 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency (RF) energy delivery under ICE guidance
Number of subjects: 53
Study 15237765 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 18
Study 15237765 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine
Number of subjects: 18
Study 15237765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 12010358 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy with adherence
Number of subjects: 0
Study 12010358 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy with non-adherence
Number of subjects: 0
Study 12010358 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy with adherence and nadir below limit
Number of subjects: 0
Study 12010358 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy with adherence and nadir above limit
Number of subjects: 0
Study 12010358 — intervention group
Group type: COMPARATOR
Intervention: Dual therapy
Number of subjects: 0
Study 9820445 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.1% amino acid peritoneal dialysis solution (DAA)
Number of subjects: 105
Study 9820445 — intervention group
Group type: COMPARATOR
Intervention: Glucose dialysate (DD)
Number of subjects: 105
Study 7633704 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen plus nasal pressure support ventilation (NPSV)
Number of subjects: 14
Study 7633704 — intervention group
Group type: COMPARATOR
Intervention: Oxygen therapy alone
Number of subjects: 14
Study 29214463 — intervention group
Group type: EXPERIMENTAL
Intervention: FOOT (60-min 9-a-side football match)
Number of subjects: 15
Study 29214463 — intervention group
Group type: COMPARATOR
Intervention: CON (rest)
Number of subjects: 15
Study 27497779 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID (Ibuprofen 1800mg/day)
Number of subjects: 24
Study 27497779 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 27497779 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (CRP<1mg/l)
Number of subjects: 24
Study 25600772 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO/HAA (CHO + 13 g AA)
Number of subjects: 10
Study 25600772 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO/LAA (CHO + 6.5 g AA)
Number of subjects: 10
Study 25600772 — intervention group
Group type: COMPARATOR
Intervention: CHO (1.2 g/kg body weight)
Number of subjects: 10
Study 23745309 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5-hour infusion of 0.5 g every six hours for 24 hours
Number of subjects: 9
Study 23745309 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-hour infusion of 0.5 g every six hours for 24 hours
Number of subjects: 9
Study 23745309 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-hour infusion of 1 g every six hours for 24 hours
Number of subjects: 9
Study 23745309 — intervention group
Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 9
Study 21420732 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine 50 mg/m² thrice weekly for 2 weeks every 4 weeks
Number of subjects: 14
Study 21420732 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly erythropoietin (in 7 patients)
Number of subjects: 14
Study 21420732 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine
Number of subjects: 14
Study 19335843 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 0
Study 19335843 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative immunosuppressives (Mycophenolate mofetil, Leflunomide, Deoxyspergualin)
Number of subjects: 0
Study 19335843 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologic agents (Tumor necrosis factor inhibitors, Alemtuzumab, Rituximab)
Number of subjects: 0
Study 19335843 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange
Number of subjects: 0
Study 19335843 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal therapy
Number of subjects: 0
Study 19335843 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative networks in Europe and the USA
Number of subjects: 0
Study 19335843 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer agents
Number of subjects: 0
Study 16412731 — intervention group
Group type: EXPERIMENTAL
Intervention: NuvaRing (contraceptive vaginal ring)
Number of subjects: 8
Study 16412731 — intervention group
Group type: COMPARATOR
Intervention: Combined Oral Contraceptive (COC)
Number of subjects: 8
Study 15283740 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant Compliance Questionnaire (ADCQ)
Number of subjects: 357
Study 11526357 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilink stent
Number of subjects: 100
Study 11526357 — intervention group
Group type: COMPARATOR
Intervention: GFX stent
Number of subjects: 100
Study 9313060 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 100 mg twice a day for 3 days
Number of subjects: 50
Study 9313060 — intervention group
Group type: COMPARATOR
Intervention: Cotrimoxazol 8 mg and pipemidic acid 100 mg administered twice a day (control group)
Number of subjects: 50
Study 8497669 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm application with 3% saline
Number of subjects: 18
Study 8497669 — intervention group
Group type: COMPARATOR
Intervention: Cold application with 3% saline
Number of subjects: 18
Study 8497669 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm application with 1/2 saline or normal saline
Number of subjects: 18
Study 8497669 — intervention group
Group type: COMPARATOR
Intervention: Cold application with 1/2 saline or normal saline
Number of subjects: 18
Study 8497669 — intervention group
Group type: EXPERIMENTAL
Intervention: All solutions
Number of subjects: 18
Study 8497669 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% saline
Number of subjects: 18
Study 8497669 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm application
Number of subjects: 18
Study 8497669 — intervention group
Group type: COMPARATOR
Intervention: Cold application
Number of subjects: 18
Study 3549162 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir (ACV) and dilute betamethasone
Number of subjects: 30
Study 3549162 — intervention group
Group type: COMPARATOR
Intervention: Adenine arabinoside (ARA‐A) and dilute betamethasone
Number of subjects: 30
Study 3549162 — intervention group
Group type: COMPARATOR
Intervention: Adenine arabinoside (ARA‐A)
Number of subjects: 30
Study 28719982 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep friction massage
Number of subjects: 0
Study 28719982 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisone injection
Number of subjects: 0
Study 28719982 — intervention group
Group type: COMPARATOR
Intervention: Splinting and stretching
Number of subjects: 0
Study 27792749 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-randomised prospective studies (NPSs)
Number of subjects: 547
Study 27792749 — intervention group
Group type: COMPARATOR
Intervention: Randomised controlled trials (RCTs)
Number of subjects: 547
Study 27792749 — intervention group
Group type: EXPERIMENTAL
Intervention: Both NPSs and RCTs
Number of subjects: 547
Study 24295873 — intervention group
Group type: EXPERIMENTAL
Intervention: Emtricitabine/Tenofovir combination therapy
Number of subjects: 105
Study 24295873 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir monotherapy
Number of subjects: 105
Study 22654006 — intervention group
Group type: EXPERIMENTAL
Intervention: IBV Valves (treatment group)
Number of subjects: 73
Study 22654006 — intervention group
Group type: COMPARATOR
Intervention: Control (sham procedure)
Number of subjects: 73
Study 20573750 — intervention group
Group type: EXPERIMENTAL
Intervention: FA + low‐ or moderate‐dose statin
Number of subjects: 2000
Study 20573750 — intervention group
Group type: COMPARATOR
Intervention: Low‐, moderate‐, or high‐dose statin monotherapy
Number of subjects: 2000
Study 20573750 — intervention group
Group type: EXPERIMENTAL
Intervention: FA monotherapy
Number of subjects: 2000
Study 20573750 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin monotherapy
Number of subjects: 2000
Study 20573750 — intervention group
Group type: EXPERIMENTAL
Intervention: FA + statin
Number of subjects: 2000
Study 20573750 — intervention group
Group type: EXPERIMENTAL
Intervention: FA with or without statin
Number of subjects: 2000
Study 18487900 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan (TCC)
Number of subjects: 0
Study 18487900 — intervention group
Group type: COMPARATOR
Intervention: Psychosocial support therapy (Control)
Number of subjects: 0
Study 15761748 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive intervention
Number of subjects: 130
Study 15761748 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical intervention
Number of subjects: 130
Study 12618567 — intervention group
Group type: EXPERIMENTAL
Intervention: PoleStriding with vitamin E
Number of subjects: 52
Study 12618567 — intervention group
Group type: EXPERIMENTAL
Intervention: PoleStriding with placebo
Number of subjects: 52
Study 12618567 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E without exercise
Number of subjects: 52
Study 12618567 — intervention group
Group type: COMPARATOR
Intervention: Placebo without exercise
Number of subjects: 52
Study 10621925 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine (30 mg/m2 on day 1 and day 8) and Cisplatin (100 mg/m2 on day 1) administered every three weeks
Number of subjects: 35
Study 10621925 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine and Cisplatin
Number of subjects: 35
Study 7669941 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbocalcitonin (40 IU)
Number of subjects: 0
Study 7669941 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmon calcitonin (50 IU and 100 IU)
Number of subjects: 0
Study 1940486 — intervention group
Group type: EXPERIMENTAL
Intervention: codeine
Number of subjects: 944
Study 1940486 — intervention group
Group type: EXPERIMENTAL
Intervention: oxycodone
Number of subjects: 944
Study 1940486 — intervention group
Group type: EXPERIMENTAL
Intervention: dextropropoxyphene
Number of subjects: 944
Study 1940486 — intervention group
Group type: EXPERIMENTAL
Intervention: buprenorphine
Number of subjects: 944
Study 1940486 — intervention group
Group type: EXPERIMENTAL
Intervention: pentazocine
Number of subjects: 944
Study 1940486 — intervention group
Group type: EXPERIMENTAL
Intervention: all opioids
Number of subjects: 944
Study 6812820 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive education programme with regular home urine glucose testing
Number of subjects: 46
Study 6812820 — intervention group
Group type: COMPARATOR
Intervention: Home blood glucose monitoring
Number of subjects: 46
Study 6812820 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive education and cross-over studies
Number of subjects: 46
Study 30073778 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg/day)
Number of subjects: 92
Study 30073778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 30073778 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (during extension phase 18-36 months)
Number of subjects: 92
Study 30073778 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 92
Study 28913735 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% plus Clindamycin 1% gel
Number of subjects: 60
Study 28913735 — intervention group
Group type: COMPARATOR
Intervention: Adapalene 0.1% plus Clindamycin 1% gel
Number of subjects: 60
Study 25645789 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA)
Number of subjects: 101
Study 25645789 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus (Tac)
Number of subjects: 101
Study 24451122 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir 10 mg with peginterferon alfa-2b/ribavirin
Number of subjects: 27
Study 24451122 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir 60 mg with peginterferon alfa-2b/ribavirin
Number of subjects: 27
Study 24451122 — intervention group
Group type: COMPARATOR
Intervention: Placebo with peginterferon alfa-2b/ribavirin
Number of subjects: 27
Study 24451122 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir 10 mg for prior non-responders
Number of subjects: 27
Study 24451122 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir 60 mg for prior non-responders
Number of subjects: 27
Study 22835054 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (TG)
Number of subjects: 88
Study 22835054 — intervention group
Group type: COMPARATOR
Intervention: Without thrombolytic therapy (WTG)
Number of subjects: 88
Study 22835054 — intervention group
Group type: COMPARATOR
Intervention: Thrombolytic therapy (TG) and Without thrombolytic therapy (WTG)
Number of subjects: 88
Study 19378646 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional Family Therapy HIV/STD risk-reduction intervention (MDFT-HIV/STD)
Number of subjects: 0
Study 17412790 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose supplementation (G)
Number of subjects: 15
Study 17412790 — intervention group
Group type: COMPARATOR
Intervention: No glucose supplementation (NG)
Number of subjects: 15
Study 15054020 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing First program (immediate housing without treatment prerequisites)
Number of subjects: 225
Study 15054020 — intervention group
Group type: COMPARATOR
Intervention: Control group (housing contingent on treatment and sobriety)
Number of subjects: 225
Study 11276031 — intervention group
Group type: EXPERIMENTAL
Intervention: Model for analysis of informatively censored data based on a two-stage linear random effects model.
Number of subjects: 0
Study 11276031 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum likelihood estimation using the EM algorithm.
Number of subjects: 0
Study 11276031 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity analyses and simulations.
Number of subjects: 0
Study 9462187 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO) for 72 hours
Number of subjects: 42
Study 9462187 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.5‐1 mg/kg/day intravenous for 6 days)
Number of subjects: 42
Study 9462187 — intervention group
Group type: EXPERIMENTAL
Intervention: Both inhaled NO and dexamethasone
Number of subjects: 42
Study 9462187 — intervention group
Group type: COMPARATOR
Intervention: Conventional management (control group)
Number of subjects: 42
Study 7949804 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 IU/kg/week of recombinant human growth hormone for over one year
Number of subjects: 28
Study 7949804 — intervention group
Group type: COMPARATOR
Intervention: None (untreated)
Number of subjects: 28
Study 2896219 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid bismuth subsalicylate (BSS)
Number of subjects: 245
Study 2896219 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-vial system (Enteric Plus medium and polyvinyl alcohol fixative)
Number of subjects: 245
Study 2896219 — intervention group
Group type: COMPARATOR
Intervention: Three-vial system (buffered glycerol saline, Cary‐Blair medium with campylobacter antibodies, and polyvinyl alcohol fixative)
Number of subjects: 245
Study 31299951 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen synthesis neoepitopes PRO-C3
Number of subjects: 145
Study 31299951 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen synthesis neoepitope PRO-C6
Number of subjects: 145
Study 31299951 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen degradation markers C1M
Number of subjects: 145
Study 31299951 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen degradation markers C3M
Number of subjects: 145
Study 31299951 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen degradation markers C6M
Number of subjects: 145
Study 31299951 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen degradation markers CRPM
Number of subjects: 145
Study 28635334 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating at night (NE; meals at 07:00, 19:00, and 01:30 h)
Number of subjects: 11
Study 28635334 — intervention group
Group type: COMPARATOR
Intervention: Not eating at night (NEN; meals at 07:00, 09:30, 16:10, and 19:00 h)
Number of subjects: 11
Study 28635334 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating at night (NE)
Number of subjects: 11
Study 28635334 — intervention group
Group type: COMPARATOR
Intervention: Not eating at night (NEN)
Number of subjects: 11
Study 26390793 — intervention group
Group type: EXPERIMENTAL
Intervention: Big Bag IOL
Number of subjects: 127
Study 26390793 — intervention group
Group type: COMPARATOR
Intervention: Akreos Adapt IOL
Number of subjects: 127
Study 23988010 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate alcohol intake (5 to 15 g/day)
Number of subjects: 5505
Study 23988010 — intervention group
Group type: EXPERIMENTAL
Intervention: Wine consumption (2 to 7 drinks/week)
Number of subjects: 5505
Study 23988010 — intervention group
Group type: COMPARATOR
Intervention: Heavy alcohol consumption
Number of subjects: 5505
Study 21430250 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus casei Shirota (LcS) supplementation (1.95 × 10(10) CFU LcS/d)
Number of subjects: 68
Study 21430250 — intervention group
Group type: COMPARATOR
Intervention: Placebo (similar milk drink without probiotic additive)
Number of subjects: 68
Study 19023276 — intervention group
Group type: EXPERIMENTAL
Intervention: met-met genotype
Number of subjects: 839
Study 19023276 — intervention group
Group type: EXPERIMENTAL
Intervention: val-met genotype
Number of subjects: 839
Study 19023276 — intervention group
Group type: COMPARATOR
Intervention: val-val genotype
Number of subjects: 839
Study 17159759 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.25 microg kg(‐1)
Number of subjects: 306
Study 17159759 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.50 microg kg(‐1)
Number of subjects: 306
Study 17159759 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 15 microg kg(‐1)
Number of subjects: 306
Study 17159759 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 20 microg kg(‐1)
Number of subjects: 306
Study 17159759 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1 mL of 1% (10 mg) added to 100 mg of propofol
Number of subjects: 306